Madison Park Capital Advisors LLC Makes New $325,000 Investment in Eli Lilly and Company (NYSE:LLY)

Madison Park Capital Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 558 shares of the company’s stock, valued at approximately $325,000.

Other hedge funds have also made changes to their positions in the company. JGP Wealth Management LLC lifted its stake in shares of Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after purchasing an additional 16 shares during the last quarter. Walkner Condon Financial Advisors LLC lifted its stake in shares of Eli Lilly and Company by 2.8% during the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after purchasing an additional 17 shares during the last quarter. Patton Albertson Miller Group LLC lifted its stake in shares of Eli Lilly and Company by 2.8% during the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after purchasing an additional 17 shares during the last quarter. Valley Wealth Managers Inc. lifted its stake in shares of Eli Lilly and Company by 1.3% during the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock worth $688,000 after purchasing an additional 17 shares during the last quarter. Finally, Sandy Cove Advisors LLC lifted its stake in shares of Eli Lilly and Company by 0.8% during the 4th quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock worth $1,307,000 after purchasing an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research note on Monday, April 15th. JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. BMO Capital Markets increased their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Bank of America increased their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 2.0 %

Shares of LLY traded up $14.29 during mid-day trading on Tuesday, reaching $745.62. The stock had a trading volume of 2,041,595 shares, compared to its average volume of 3,051,032. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 52-week low of $370.68 and a 52-week high of $800.78. The business’s fifty day moving average is $763.89 and its 200 day moving average is $664.05. The firm has a market cap of $708.46 billion, a price-to-earnings ratio of 128.56, a P/E/G ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.09 earnings per share. On average, sell-side analysts predict that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.